MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is positioning its artificial intelligence-driven voice analysis technology as a scalable alternative to conventional drug and alcohol testing methods that require biological samples. In a recent TechMediaWire Podcast, CEO Justin Hanka outlined the company’s plans to commercialize the technology, which uses non-invasive speech assessment to detect intoxication from alcohol and drug use.
According to Hanka, MindBio has built prediction models using more than 50 million data points collected through years of clinical research. These models can identify intoxication indicators associated with alcohol and drug use with remarkable accuracy, relying solely on the human voice. The company believes this approach offers a scalable alternative to traditional testing methods, which often require blood, urine, or saliva samples and can be logistically challenging in many work environments.
MindBio is developing enterprise deployment systems that combine proprietary software with Edge-AI kiosks capable of delivering assessments in less than three seconds. The company expects to begin live workplace testing during the second quarter of 2026. Potential applications span safety-sensitive industries such as mining, aviation, construction, and law enforcement, where rapid and non-invasive impairment detection could enhance workplace safety and compliance.
Beyond workplace impairment detection, management sees broader opportunities for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions. The technology’s ability to analyze subtle voice changes could open new avenues for early detection and monitoring of various health issues.
The news is significant because it addresses a growing need for efficient, non-invasive testing solutions in industries where impairment poses serious risks. Traditional testing methods can be time-consuming, invasive, and costly, often requiring specialized personnel and equipment. MindBio’s approach could streamline testing processes, reduce downtime, and improve safety outcomes. Additionally, the potential diagnostic applications of voice analysis could have far-reaching implications for healthcare, enabling earlier intervention for conditions that affect speech patterns.
MindBio Therapeutics is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments.
For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
